Digital Medicine
The Digital Medicine Strategy backs early-stage start-ups innovating at the intersection of biology, data and computation. We work with founders to build companies leveraging AI, machine learning, and data analytics to transform healthcare and medicine.
Our approach is evidence-based, rooted in rigorous scientific research and clinical validation, and built on Sofinnova's 50 years of experience in the life sciences.
| Close | Fund | AMT |
|---|---|---|
| 2023 | Sofinnova Digital Medicine I | $200 million |
Close: 2023
Fund: Sofinnova Digital Medicine I
AMT: $200 million
"We bring our experience in biological innovation coupled with powerful computing and AI capabilities to build deeply technical companies to product-market fit. This is what makes our approach unique."
"We designed this strategy to help founders leverage our knowledge of a highly-regulated and complex healthcare industry while drawing on the strengths of tech-industry approaches like rapid product iteration and swift commercialization."
The
Team
Related News
Latent Labs announces Latent-X2: AI-generated antibodies with drug-like developability and low ex vivo immunogenicity
Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do
deepc recognized by Sofinnova Partners as a top performer in ESG excellence
BioCorteX announces strategic partnership with CD Biopharma to accelerate global precision oncology
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology